卵巢癌TP53突变与BRCA共突变及铂敏感性的关系
研究对393例卵巢癌患者行下一代测序,按三种方案分类TP53突变,比较有无BRCA突变者的突变分布;在281例高级别浆液性癌中分析总生存和铂耐药。BRCA突变者TP53突变频率更高,TP53突变与总生存无关,校正BRCA后与铂敏感相关。
要点
- BRCA突变卵巢癌中TP53突变频率显著更高(92.3% vs 72.2%)。
- TP53突变与总生存无显著关联,即使按BRCA状态分层。
- 校正BRCA状态后,TP53突变仍与铂敏感相关(OR 0.41)。
核心结论
- BRCA突变与TP53突变显著共存。
- 校正BRCA突变后,TP53突变与铂敏感相关,且不依赖TP53突变类型。
研究设计与样本
- 前瞻性随访393例卵巢癌患者,行下一代测序。
- TP53突变按Structural、Functional和Hotspot三种方案分类。
- 在281例高级别浆液性癌中比较总生存,采用Kaplan-Meier、logrank检验和多因素Cox回归。
- 用多因素logistic回归分析TP53突变类型对铂耐药的影响。
主要发现
- 全队列TP53突变率76.8%(302/393),高级别浆液性癌中87.9%(247/281)。
- BRCA突变者TP53突变频率显著更高(84/91,92.3% vs 218/302,72.2%,p < 0.001)。
- TP53突变与总生存无显著关联,按BRCA状态分层后仍无关联。
- TP53突变与铂敏感相关,校正BRCA状态后OR 0.41(p = 0.048)。
- TP53突变分类方案的选择未改变任何显著结局。
临床怎么用
- 卵巢癌中BRCA突变与TP53突变常共存,检测BRCA时需关注TP53状态。
- TP53突变状态可能提示铂敏感性,但需结合BRCA状态综合评估。
- TP53突变分型方案对预后判断影响不大,临床可灵活选用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Mutations in the TP53 tumor suppressor gene are common in ovarian carcinoma (OC) but their impact on outcomes is controversial. We sought to define the relationship of TP53 mutations to cancer outcomes and their interactions with co-occurrent BRCA1 or BRCA2 (BRCA) mutations, comparing three different TP53 mutation classification schemes. METHODS: We performed next generation sequencing on 393 cases of OC prospectively followed for survival. TP53 mutations were classified according to three schemes termed Structural, Functional, and Hotspot. Mutation distribution was compared between cases with and without BRCA mutations. In a subset of 281 cases of high grade serous carcinoma (HGSC), overall survival was compared using Kaplan-Meier curves, logrank testing, and multivariate Cox regression analysis, both stratified and adjusted for BRCA mutation status. Multivariate logistic regression was used to analyze the effects of TP53 mutation type on platinum resistance. RESULTS: TP53 mutations were identified in 76.8% of the total cohort (n = 302/393) and 87.9% of HGSC (n = 247/281). Cases with BRCA mutations demonstrated significantly higher TP53 mutation frequency overall (n = 84/91, 92.3% vs. n = 218/302, 72.2%, p < 0.001). TP53 mutations were not associated with overall survival, even when stratified by BRCA mutation. TP53 mutations were associated with platinum sensitivity, even after adjusting for BRCA mutation status (OR 0.41, p = 0.048). The choice of TP53 mutation classification scheme was not found to alter any significant outcome. CONCLUSIONS: BRCA mutations significantly co-occur with TP53 mutations. After adjusting for BRCA mutations, TP53 mutations are associated with platinum sensitivity, and this effect is not dependent on TP53 mutation type.
引用
- Ghezelayagh TS, Pennington KP, Norquist BM, et al. Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations. Gynecol Oncol. 2020. PMID: 33375991. doi:10.1016/j.ygyno.2020.12.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。